Literature DB >> 4913866

Thalidomide in the treatment of erythema nodosum leprosum. With a note on selected laboratory abnormalities in erythema nodosum leprosum.

R C Hastings, J R Trautman, C D Enna, R R Jacobson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4913866     DOI: 10.1002/cpt1970114481

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  7 in total

Review 1.  Leprosy.

Authors:  R C Hastings; T P Gillis; J L Krahenbuhl; S G Franzblau
Journal:  Clin Microbiol Rev       Date:  1988-07       Impact factor: 26.132

2.  Thalidomide derivatives and the immune system. I. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood.

Authors:  R Neubert; A C Nogueira; D Neubert
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

Review 3.  Thalidomide: an antineoplastic agent.

Authors:  Robert J Amato
Journal:  Curr Oncol Rep       Date:  2002-01       Impact factor: 5.945

Review 4.  Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.

Authors:  T E Clark; N Edom; J Larson; L J Lindsey
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

5.  Peripheral Neuropathy Due to Leprosy.

Authors:  Sharon P. Nations; Richard J. Barohn
Journal:  Curr Treat Options Neurol       Date:  2002-05       Impact factor: 3.972

Review 6.  Revisiting potential value of antitumor drugs in the treatment of COVID-19.

Authors:  Wenfang Zheng; Zekun Zeng; Shumei Lin; Peng Hou
Journal:  Cell Biosci       Date:  2022-10-01       Impact factor: 9.584

7.  Thalidomide Exerts Anti-Inflammatory Effects in Cutaneous Lupus by Inhibiting the IRF4/NF-ҡB and AMPK1/mTOR Pathways.

Authors:  Sandra Domingo; Cristina Solé; Teresa Moliné; Berta Ferrer; Josefina Cortés-Hernández
Journal:  Biomedicines       Date:  2021-12-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.